These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29773319)

  • 41. Recent advances in understanding multiple myeloma.
    Hari P
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):267-271. PubMed ID: 28633036
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Multiple myeloma: pathophysiology and progress in management].
    Kuroda J; Chinen Y
    Rinsho Ketsueki; 2017; 58(5):487-497. PubMed ID: 28592764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dendrimer-nanoparticle conjugates in nanomedicine.
    Parat A; Bordeianu C; Dib H; Garofalo A; Walter A; Bégin-Colin S; Felder-Flesch D
    Nanomedicine (Lond); 2015; 10(6):977-92. PubMed ID: 25867861
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.
    de Mel S; Chen Y; Gopalakrishnan SK; Ooi M; Teo C; Tan D; Teo ML; Tso AC; Lee LK; Nagarajan C; Goh YT; Chng WJ
    Singapore Med J; 2017 Feb; 58(2):55-71. PubMed ID: 27609508
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Investigative tools for diagnosis and management.
    Munshi NC
    Hematology Am Soc Hematol Educ Program; 2008; ():298-305. PubMed ID: 19074100
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy.
    Liang C; Xu L; Song G; Liu Z
    Chem Soc Rev; 2016 Nov; 45(22):6250-6269. PubMed ID: 27333329
    [TBL] [Abstract][Full Text] [Related]  

  • 47. From innovative polymers to advanced nanomedicine: key challenges, recent progress and future perspectives: the second Symposium on Innovative Polymers for Controlled Delivery Suzhou, China, 11–14 September 2012 .
    Feijen J; Hennink WE; Zhong Z
    Nanomedicine (Lond); 2013 Feb; 8(2):177-80. PubMed ID: 23394154
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Multiple myeloma: a proper selection of the treatment regimen for an individual patient].
    Kanoh T
    Nihon Rinsho; 1995 Mar; 53(3):671-7. PubMed ID: 7699903
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier.
    Tam VH; Sosa C; Liu R; Yao N; Priestley RD
    Int J Pharm; 2016 Dec; 515(1-2):331-342. PubMed ID: 27769885
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The potential of biomimetic nanoparticles for tumor-targeted drug delivery.
    Li B; Wang F; Gui L; He Q; Yao Y; Chen H
    Nanomedicine (Lond); 2018 Aug; 13(16):2099-2118. PubMed ID: 30226404
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical updates and nursing considerations for patients with multiple myeloma.
    Faiman B
    Clin J Oncol Nurs; 2007 Dec; 11(6):831-40. PubMed ID: 18063542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Problems monitoring response in multiple myeloma.
    Collins CD
    Cancer Imaging; 2005 Nov; 5 Spec No A(Spec No A):S119-26. PubMed ID: 16361127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.
    Merz M; Raab MS; Goldschmidt H; Hillengass J
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2521-2526. PubMed ID: 28653099
    [TBL] [Abstract][Full Text] [Related]  

  • 54. News & views in ... Nanomedicine.
    Nanomedicine (Lond); 2012 Aug; 7(8):1121-4. PubMed ID: 22931445
    [No Abstract]   [Full Text] [Related]  

  • 55. [Management of multiple myeloma in Hungary in 2016].
    Varga G; Mikala G; Váróczy L; Illés Á
    Orv Hetil; 2016 Jan; 157(4):123-37. PubMed ID: 26772825
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multiple myeloma: new aspects of biology and treatment.
    Ozaki S; Kosaka M
    J Med Invest; 1998 Feb; 44(3-4):127-36. PubMed ID: 9597800
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of Cancer/Testis Antigens in Multiple Myeloma pathogenesis and their application in disease monitoring and therapy.
    Shires K; Van Wyk T
    Crit Rev Oncol Hematol; 2018 Dec; 132():17-26. PubMed ID: 30447924
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cancer nanomedicine: from targeted delivery to combination therapy.
    Xu X; Ho W; Zhang X; Bertrand N; Farokhzad O
    Trends Mol Med; 2015 Apr; 21(4):223-32. PubMed ID: 25656384
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fundamentals in the management of multiple myeloma.
    Fadilah SA
    Med J Malaysia; 2010 Sep; 65(3):231-9. PubMed ID: 21939177
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.